LISATA THERAPEUTICS, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
LISATA THERAPEUTICS, INC. (LSTA) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$16.17 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2019-03-14
- LISATA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2018-12-31 was -$3.56M.
- LISATA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2018-09-30 was -$3.55M.
- LISATA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2018-06-30 was -$4.08M.
- LISATA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2018-03-31 was -$4.98M.
- LISATA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2018 was -$16.17M.
- LISATA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2017 was -$16.17M.
- LISATA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2016 was -$31.26M.
- LISATA THERAPEUTICS, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2014 was -$55.47M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|
| 2018-12-31 | -$3.56M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$7.11M derived: sum of 2 quarters · filed 2019-03-14 | -$11.18M derived: sum of 3 quarters · filed 2019-03-14 | -$16.17M 10-K · filed 2019-03-14 | |
| 2018-09-30 | -$3.55M 10-Q · filed 2018-11-08 | -$7.63M derived: sum of 2 quarters · filed 2018-11-08 | -$12.61M 10-Q · filed 2018-11-08 | -$16.58M derived: sum of 4 quarters · filed 2019-03-14 | |
| 2018-06-30 | -$4.08M 10-Q · filed 2018-08-09 | -$9.06M 10-Q · filed 2018-08-09 | -$13.03M derived: sum of 3 quarters · filed 2019-03-14 | -$16.57M derived: sum of 4 quarters · filed 2019-03-14 | |
| 2018-03-31 | -$4.98M 10-Q · filed 2018-05-10 | -$8.95M derived: sum of 2 quarters · filed 2019-03-14 | -$12.50M derived: sum of 3 quarters · filed 2019-03-14 | -$14.52M derived: sum of 4 quarters · filed 2019-03-14 | |
| 2017-12-31 | -$3.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | -$7.51M derived: sum of 2 quarters · filed 2019-03-14 | -$9.54M derived: sum of 3 quarters · filed 2019-03-14 | -$16.17M 10-K · filed 2019-03-14 | -$16.17M 10-K · filed 2018-03-22 |
| 2017-09-30 | -$3.55M 10-Q · filed 2018-11-08 | -$5.57M derived: sum of 2 quarters · filed 2018-11-08 | -$12.21M 10-Q · filed 2018-11-08 | -$17.87M derived: sum of 4 quarters · filed 2018-11-08 | |
| 2017-06-30 | -$2.02M 10-Q · filed 2018-08-09 | -$8.66M 10-Q · filed 2018-08-09 | -$14.32M derived: sum of 3 quarters · filed 2018-08-09 | -$20.42M derived: sum of 4 quarters · filed 2018-08-09 | |
| 2017-03-31 | -$6.64M 10-Q · filed 2018-05-10 | -$12.30M derived: sum of 2 quarters · filed 2018-05-10 | -$18.39M derived: sum of 3 quarters · filed 2018-05-10 | -$26.13M derived: sum of 4 quarters · filed 2018-05-10 | |
| 2016-12-31 | -$5.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-22 | -$11.76M derived: sum of 2 quarters · filed 2018-03-22 | -$19.49M derived: sum of 3 quarters · filed 2018-03-22 | -$31.26M 10-K · filed 2018-03-22 | |
| 2016-09-30 | -$6.09M 10-Q · filed 2017-11-09 | -$13.82M derived: sum of 2 quarters · filed 2017-11-09 | -$25.59M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | -$7.73M 10-Q · filed 2017-08-10 | -$19.50M 10-Q · filed 2017-08-10 | |||
| 2014-12-31 | -$55.47M 10-K · filed 2015-03-02 | ||||
| 2013-12-31 | -$12.72M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$22.00M derived: sum of 2 quarters · filed 2015-03-02 | -$30.62M derived: sum of 3 quarters · filed 2015-03-02 | -$39.49M 10-K · filed 2015-03-02 | |
| 2013-09-30 | -$9.28M 10-Q · filed 2013-11-07 | -$17.90M derived: sum of 2 quarters · filed 2013-11-07 | -$26.77M 10-Q · filed 2013-11-07 | -$39.10M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-06-30 | -$8.63M 10-Q · filed 2013-08-08 | -$17.49M 10-Q · filed 2013-08-08 | -$29.83M derived: sum of 3 quarters · filed 2015-03-02 | -$38.37M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2013-03-31 | -$8.86M 10-Q · filed 2013-05-09 | -$21.20M derived: sum of 2 quarters · filed 2015-03-02 | -$29.75M derived: sum of 3 quarters · filed 2015-03-02 | -$36.99M derived: sum of 4 quarters · filed 2015-03-02 | |
| 2012-12-31 | -$12.34M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | -$20.88M derived: sum of 2 quarters · filed 2015-03-02 | -$28.12M derived: sum of 3 quarters · filed 2015-03-02 | -$36.10M 10-K · filed 2015-03-02 | |
| 2012-09-30 | -$8.55M 10-Q · filed 2013-11-07 | -$15.79M derived: sum of 2 quarters · filed 2013-11-07 | -$23.77M 10-Q · filed 2013-11-07 | -$31.39M derived: sum of 4 quarters · filed 2013-11-07 | |
| 2012-06-30 | -$7.24M 10-Q · filed 2013-08-08 | -$15.22M 10-Q · filed 2013-08-08 | -$22.85M derived: sum of 3 quarters · filed 2013-08-08 | -$29.42M derived: sum of 4 quarters · filed 2013-08-08 | |
| 2012-03-31 | -$7.98M 10-Q · filed 2013-05-09 | -$15.61M derived: sum of 2 quarters · filed 2013-05-09 | -$22.18M derived: sum of 3 quarters · filed 2013-05-09 | -$32.27M derived: sum of 4 quarters · filed 2013-05-09 | |
| 2011-12-31 | -$7.63M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | -$14.20M derived: sum of 2 quarters · filed 2013-03-11 | -$24.29M derived: sum of 3 quarters · filed 2013-03-11 | -$34.57M 10-K · filed 2013-03-11 | |
| 2011-09-30 | -$6.57M 10-Q · filed 2012-11-13 | -$16.66M derived: sum of 2 quarters · filed 2012-11-13 | -$26.94M 10-Q · filed 2012-11-13 | ||
| 2011-06-30 | -$10.09M 10-Q · filed 2012-08-14 | -$20.20M 10-Q · filed 2012-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |